D.A. Davidson & CO. Purchases 12,399 Shares of Novo Nordisk A/S (NYSE:NVO)

D.A. Davidson & CO. grew its position in Novo Nordisk A/S (NYSE:NVO) by 31.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,212 shares of the company’s stock after acquiring an additional 12,399 shares during the period. D.A. Davidson & CO.’s holdings in Novo Nordisk A/S were worth $6,098,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. 1620 Investment Advisors Inc. bought a new position in Novo Nordisk A/S during the second quarter worth $25,000. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S in the 2nd quarter valued at about $25,000. Gilliland Jeter Wealth Management LLC lifted its position in Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after acquiring an additional 120 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Novo Nordisk A/S during the third quarter worth approximately $28,000. Finally, Halpern Financial Inc. grew its position in shares of Novo Nordisk A/S by 113.0% in the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $106.12 on Thursday. The company has a 50 day moving average of $113.80 and a 200-day moving average of $128.33. The company has a market cap of $476.22 billion, a PE ratio of 34.34, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15.

Wall Street Analyst Weigh In

A number of brokerages have commented on NVO. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.